Compounds > carmustine

carmustine and fludarabine

carmustine has been researched along with fludarabine in 27 studies

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.70)18.2507
2000's16 (59.26)29.6817
2010's9 (33.33)24.3611
2020's1 (3.70)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J1
Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M1
Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G1
Kashyap, A; Snowden, J1
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J1
Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G1
Bertz, H; Finke, J; Potthoff, K1
Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC1
Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M1
Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM1
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S1
Cordonnier, M1
Bertz, H; Finke, JM; Hahn, J; Holler, E; Ihorst, G; Marks, R; Potthoff, K; Spyridonidis, A1
Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L1
Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J1
Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R1
Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M1
Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO1
Bentz, M; Binnenhei, M; Bohl, SR; Bullinger, L; Bunjes, D; Döhner, H; Döhner, K; Drognitz, K; Kuchenbauer, F; Kündgen, L; Moulin, JC; Nguyen, TM; Ringhoffer, M; Schlenk, RF; Teleanu, V; von Harsdorf, S; Wais, V1
Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M1
Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R1

Reviews

1 review(s) available for carmustine and fludarabine

ArticleYear
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
    The Journal of rheumatology. Supplement, 2001, Volume: 64

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2001

Trials

6 trial(s) available for carmustine and fludarabine

ArticleYear
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine

2000
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-15, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Living Donors; Male; Melphalan; Middle Aged; Prognosis; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2006
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
    Blood, 2008, Jul-15, Volume: 112, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2013

Other Studies

20 other study(ies) available for carmustine and fludarabine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
    Bone marrow transplantation, 1993, Volume: 12, Issue:3

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine

1993
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2000
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
    Onkologie, 2007, Volume: 30, Issue:1-2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine

2007
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine

2008
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
[Visual cortes--is it a concern?].
    Bulletin de la Societe belge d'ophtalmologie, 2007, Issue:304

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blindness, Cortical; Carmustine; Cathartics; Cholinergic Antagonists; Cisplatin; Cyclosporine; Dopamine Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Interferons; Serotonin Agents; Tacrolimus; Vidarabine; Vincristine; Visual Cortex

2007
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
    Bone marrow transplantation, 2009, Volume: 43, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult

2009
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine

2010
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
    Human antibodies, 2010, Volume: 19, Issue:1

    Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Vindesine

2010
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:8

    Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2013
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Bone marrow transplantation, 2018, Volume: 53, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Staging; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2018
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
    Bone marrow transplantation, 2019, Volume: 54, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2019
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2021, Volume: 56, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2021